Ghid de management al infecțiilor asociate îngrijirilor de sănătate un punct de vedere. Prof. Adrian Streinu-Cercel MD, PhD, HC 2017

Σχετικά έγγραφα
ΚΟΝΤΟΥ ΠΑΣΧΑΛΙΝΑ ΠΝΕΥΜΟΝΟΛΟΓΟΣ ΕΝΤΑΤΙΚΟΛΟΓΟΣ ΕΠΙΜΕΛΗΤΡΙΑ Β Α ΜΕΘ «Γ. ΠΑΠΑΝΙΚΟΛΑΟΥ»

c Key words: cultivation of blood, two-sets blood culture, detection rate of germ Vol. 18 No

Κεφάλαιο 5 - Λοιμώξεις στη Μονάδα Εντατικής Θεραπείας

V G III MIC. Table 1. Methods and reporting values of antimicrobial susceptibility testing and their interpretations


20/11/2013. Παλαιότερα αντιβιοτικά για πολυανθεκτικά Gram αρνητικά βακτήρια. Παλαιότερα αντιβιοτικά για πολυανθεκτικά. Πολυανθεκτικά Gram( ) βακτήρια

Φλώρα Κοντοπίδου Παθολόγος-Λοιμωξιολόγος (Phd) Υπεύθυνη Γραφείου Μικροβιακής Αντοχής ΚΕΕΛΠΝΟ

Subiecte Clasa a VII-a

Functii definitie, proprietati, grafic, functii elementare A. Definitii, proprietatile functiilor X) functia f 1

DISTANŢA DINTRE DOUĂ DREPTE NECOPLANARE

Μικροβιακή Αντοχή : Μία πρόκληση για την Κύπρο και τον κόσμο. Eirini Christaki Lecturer of Internal Medicine Medical School, University of Cyprus

R R, f ( x) = x 7x+ 6. Determinați distanța dintre punctele de. B=, unde x și y sunt numere reale.

Functii definitie, proprietati, grafic, functii elementare A. Definitii, proprietatile functiilor

COLEGIUL NATIONAL CONSTANTIN CARABELLA TARGOVISTE. CONCURSUL JUDETEAN DE MATEMATICA CEZAR IVANESCU Editia a VI-a 26 februarie 2005.

Corectură. Motoare cu curent alternativ cu protecție contra exploziei EDR * _0616*

T R A I A N ( ) Trigonometrie. \ kπ; k. este periodică (perioada principală T * =π ), impară, nemărginită.

Parts Manual. Trio Mobile Surgery Platform. Model 1033

Νοσοκομειακή πνευμονία(hap)

Ecuaţia generală Probleme de tangenţă Sfera prin 4 puncte necoplanare. Elipsoidul Hiperboloizi Paraboloizi Conul Cilindrul. 1 Sfera.

Componente şi Circuite Electronice Pasive. Laborator 3. Divizorul de tensiune. Divizorul de curent

Προτάσεις για την αντιμετώπιση του προβλήματος της μικροβιακής αντοχής. Ν.Κομιτόπουλος Διευθυντής Β Παθολογικής Κλινικής

Curs 10 Funcţii reale de mai multe variabile reale. Limite şi continuitate.

met la disposition du public, via de la documentation technique dont les rιfιrences, marques et logos, sont

Estimation of grain boundary segregation enthalpy and its role in stable nanocrystalline alloy design

Πανδής Σ., Αραμπατζής Μ. & Α. Βελεγράκη. Ειδικό Εργαστήριο Μυκητολογίας (Κ.Α 70/4/5905, Κ.Α 70/3/6915)

Planul determinat de normală şi un punct Ecuaţia generală Plane paralele Unghi diedru Planul determinat de 3 puncte necoliniare

Νόµοςπεριοδικότητας του Moseley:Η χηµική συµπεριφορά (οι ιδιότητες) των στοιχείων είναι περιοδική συνάρτηση του ατοµικού τους αριθµού.

Βερανζέρου 50 Αθήνα ΤΚ10438 Φ. Καλύβα (210) (210) ΠΡΟΣ :

Το άτομο του Υδρογόνου

Profesor Blaga Mirela-Gabriela DREAPTA

Curs 2 DIODE. CIRCUITE DR

5.4. MULTIPLEXOARE A 0 A 1 A 2

Το Εργαστήριο μπορεί να συστήσει τον τρόπο λήψης, καθώς και τα κατάλληλα υλικά λήψης και μεταφοράς των δειγμάτων.

Θεραπευτικές εξελίξεις στις λοιμώξεις. Ε. Κωστής 2018

Analiza în curent continuu a schemelor electronice Eugenie Posdărăscu - DCE SEM 1 electronica.geniu.ro

RĂSPUNS Modulul de rezistenţă este o caracteristică geometrică a secţiunii transversale, scrisă faţă de una dintre axele de inerţie principale:,

riptografie şi Securitate

ΛΟΙΜΩΞΕΙΣ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΠΟΔΙ Επιδημιολογία των παθογόνων στελεχών στην Ελλάδα

Etest. cefepime. oxacillin Staphylococcus aureus oxacillin. imipenem piperacillin ceftazidime cefpirome

!"#$%& '!(#)& a<.21c67.<9 /06 :6>/ 54.6: 1. ]1;A76 _F -. /06 4D26.36 <> A.:4D6:6C C4/4 /06 D:43? C</ O=47?6C b*dp 12 :1?6:E /< D6 3:4221N6C 42 D:A6 O=

Fig Impedanţa condensatoarelor electrolitice SMD cu Al cu electrolit semiuscat în funcţie de frecvenţă [36].

HONDA. Έτος κατασκευής

MARCAREA REZISTOARELOR

BD BBL GO Slide. Ο ΗΓΙΕΣ ΧΡΗΣΗΣ ΕΤΟΙΜΑ ΠΡΟΣ ΧΡΗΣΗ ΥΛΙΚΑ ΚΑΛΛΙΕΡΓΕΙΑΣ ΣΕ ΕΜΒΑΠΤΙΖΟΜΕΝΕΣ ΑΝΤΙΚΕΙΜΕΝΟΦΟΡΟΥΣ ΠΛΑΚΕΣ DA Αναθ.

Εμπορική αλληλογραφία Ηλεκτρονική Αλληλογραφία

ΝΟΜΟΣ ΤΗΣ ΠΕΡΙΟ ΙΚΟΤΗΤΑΣ : Οι ιδιότητες των χηµικών στοιχείων είναι περιοδική συνάρτηση του ατοµικού τους αριθµού.

CONCURSUL DE MATEMATICĂ APLICATĂ ADOLF HAIMOVICI, 2017 ETAPA LOCALĂ, HUNEDOARA Clasa a IX-a profil științe ale naturii, tehnologic, servicii

Ελληνική Εταιρεία Χημειοθεραπείας

BARAJ DE JUNIORI,,Euclid Cipru, 28 mai 2012 (barajul 3)

WHONET % 100% 99. 4% % 42. 2% β- MDRA HLGR MDRP 15. 8% 4. 1% 4. 0% 2. 5%

ΥΠΗΡΕΣΙΕΣ ΠΡΟΣΩΠΙΚΟΥ ΔΙΑΧΕΙΡΙΣΗ ΑΠΟΔΟΣΗΣ ΚΑΙ ΣΤΕΛΕΧΩΣΗ

Solving an Air Conditioning System Problem in an Embodiment Design Context Using Constraint Satisfaction Techniques

SIEMENS Squirrel Cage Induction Standard Three-phase Motors

Asupra unei inegalităţi date la barajul OBMJ 2006

! "#" "" $ "%& ' %$(%& % &'(!!")!*!&+ ,! %$( - .$'!"

Ψευδομεμβρανώδης κολίτιδα σε ασθενείς με ΙΦΝΕ. Θεώνη Κανελλοπούλου Ειδικευόμενη παθολογίας

Integrala nedefinită (primitive)

(a) se numeşte derivata parţială a funcţiei f în raport cu variabila x i în punctul a.

Καλλιόπη Ζάχου Παθολόγος Παθολογική Κλινική & Ερευνητικό Εργαστήριο Παν/μίου Θεσσαλίας

ΓΗ ΚΑΙ ΣΥΜΠΑΝ. Εικόνα 1. Φωτογραφία του γαλαξία μας (από αρχείο της NASA)

a n (ζ z 0 ) n. n=1 se numeste partea principala iar seria a n (z z 0 ) n se numeste partea

Control confort. Variator de tensiune cu impuls Reglarea sarcinilor prin ap sare, W/VA

Proiectarea filtrelor prin metoda pierderilor de inserţie

V.7. Condiţii necesare de optimalitate cazul funcţiilor diferenţiabile

ΠΑΡΑΡΤΗΜΑ I ΠΕΡΙΛΗΨΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ

V O. = v I v stabilizator

Curs 4 Serii de numere reale

5.5. REZOLVAREA CIRCUITELOR CU TRANZISTOARE BIPOLARE

Olimpiada Naţională de Matematică Etapa locală Clasa a IX-a M 1

21/11/2012. Τρόποι μετάδοσης: Επίπτωση Νοσοκομειακών λοιμώξεων. Κόστος νοσοκομειακών λοιμώξεων: ΜΕΘ: Ενα επικίνδυνο μέρος!

Laborator 11. Mulţimi Julia. Temă

ΑΥΞΗΜΕΝΗ ΣΥΧΝΟΤΗΤΑ GRAM- ΘΕΤΙΚΩΝ ΚΟΚΚΩΝ ΚΑΙ ΡΟΛΥΑΝΘΕΚΤΙΚΩΝ ΒΑΚΤΗΙΔΙΩΝ ΣΤΗΝ ΑΥΤΟΜΑΤΗ ΒΑΚΤΗΙΑΚΗ ΡΕΙΤΟΝΙΤΙΔΑ

,, #,#, %&'(($#(#)&*"& 3,,#!4!4! +&'(#,-$#,./$012 5 # # %, )

Αντιμετώπιση κλινικών προβλημάτων σε κιρρωτικούς ασθενείς με ΛΟΙΜΩΞΗ. Δρ. Νικόλαος Παπαδόπουλος παθολόγος-ηπατολόγος Α παθολογική 401 Γ.Σ.Ν.

Conice. Lect. dr. Constantin-Cosmin Todea. U.T. Cluj-Napoca

Η ΣΗΜΑΣΙΑ ΤΗΣ ΕΠΙΤΗΡΗΣΗΣ ΤΗΣ ΚΑΤΑΝΑΛΩΣΗΣ ΤΩΝ ΑΝΤΙΜΙΚΡΟΒΙΑΚΩΝ ΟΥΣΙΩΝ ΣΤΟ ΝΟΣΟΚΟΜΕΙΑΚΟ ΧΩΡΟ

Ι ΙΟΤΗΤΕΣ ΤΩΝ ΑΤΟΜΩΝ. Παππάς Χρήστος Επίκουρος Καθηγητής

Επιδημιολογική μελέτη Ευρωπαϊκή Ένωση 6,1-9,9 % των νοσηλευομένων ασθενών έχουν ενδονοσοκομειακή λοίμωξη

ΤΑΥΤΟΠΟΙΗΣΗ GRAM (-) ΒΑΚΤΗΡΙΔΙΩΝ

5. FUNCŢII IMPLICITE. EXTREME CONDIŢIONATE.

In vitro δραστικότητα των ceftaroline, ceftobiprole και telavancin έναντι κλινικών στελεχών Staphylococcus aureus στη Θεσσαλία

Escherichia coli. Escherichia coli Proteus mirabilis Klebsiella pneumoniae

Metode iterative pentru probleme neliniare - contractii

Aplicaţii ale principiului I al termodinamicii la gazul ideal

ΕΛΛΗΝΙΚΗ OMAΔΑ ΜΕΛΕΤΗΣ ΤΗΣ ΣΗΨΗΣ (HELLENIC SEPSIS STUDY GROUP) ΣΥΝΑΝΤΗΣΗ 02/10 10/2008 ΠΑΡΟΥΣΕΣ ΚΑΙ ΜΕΛΛΟΝΤΙΚΕΣ ΠΡΟΟΠΤΙΚΕΣ

III. Serii absolut convergente. Serii semiconvergente. ii) semiconvergentă dacă este convergentă iar seria modulelor divergentă.

Definiţia generală Cazul 1. Elipsa şi hiperbola Cercul Cazul 2. Parabola Reprezentari parametrice ale conicelor Tangente la conice

Πρωτοπαθής και δευτεροπαθής αντοχή του μυκοβακτηριδίου

C 1 D 1. AB = a, AD = b, AA1 = c. a, b, c : (1) AC 1 ; : (1) AB + BC + CC1, AC 1 = BC = AD, CC1 = AA 1, AC 1 = a + b + c. (2) BD 1 = BD + DD 1,

页面

ΜΕΤΑ-ΝΟΣΟΚΟΜΕΙΑΚΕΣ ΛΟΙΜΩΞΕΙΣ Ο ΡΟΛΟΣ ΤΟΥ ΙΑΤΡΟΥ ΤΗΣ ΠΟΛΗΣ ΣΑΛΠΙΓΚΤΗΣ ΙΩΑΝΝΗΣ ΠΑΘΟΛΟΓΟΣ

Electronic Supplementary Information

Ministerul Educaţiei Naționale Centrul Naţional de Evaluare şi Examinare

Valori limită privind SO2, NOx şi emisiile de praf rezultate din operarea LPC în funcţie de diferite tipuri de combustibili

«Αξιολόγηση της Αντιβακτηριακής Δράσης του μελιού Όλυμπος (Θεσσαλία, Κεντρική Ελλάδα) σε Σύγκριση με το μέλι ΜANUKA 10+»

!"! # $ %"" & ' ( ! " # '' # $ # # " %( *++*

Heterobimetallic Pd-Sn Catalysis: Michael Addition. Reaction with C-, N-, O-, S- Nucleophiles and In-situ. Diagnostics

ΑΙΜΟΚΑΘΑΡΣΗ Σύγχρονες προσεγγίσεις σε παλαιά προβλήματα Λοιμώξεις Κεντρικών Καθετήρων

Specii de Candida izolate din infectiile micotice

Transcript:

Ghid de management al infecțiilor asociate îngrijirilor de sănătate un punct de vedere Prof. Adrian Streinu-Cercel MD, PhD, HC 2017

!"#$%#&'(%#)*#$+,-%.#$+/)"%,-#0%#+.',"#1#

2)+.#3#

4'(#')+.5#)%#.'"#$+,-%6"#1#

We live in a BACTERIAL World!! 3 miliarde de ani de dezvoltare a bacteriilor înainte de apari!ie a animalelor "i plantelor pe P mânt!! Microbii reprezint 60% din biomasa p mântului!! Se estimeaz c < 0.5 % din cele 2-3 miiarde de specii bacteriene au fost identificate!! Numai o mic parte a acestor microbi ar fi patogeni pentru om A.S. Fauci CID, 2001!! Compozi!ia celular a corpului uman:!! 10 13 eukaryotic cells!! 10 14 microbiene cells!! Represents endogen flora!! 500 commensal bacterial species colonies GI tract

Rated key strategies of anhmicrobial stewadship Dellit 2007 AnHmicrobial management team: mulhdisciplinary, compensated (AII-AIII) Core achvihes of the team: Audit & feedback (AI) Formulary restrichon/preauthorizahon (AII) OpHonal achvihes: Guidelines/pathways (AI) IV/PO conversion (AI) De-escalaHon therapy (AII) Dose ophmizahon (AII) EducaHon (AIII) Order forms (BII) Cycling (CII) CombinaHon therapy (CII) Process measures Outcome measures to determine the impact of anhmicrobial stewardship on anhmicrobial use and resistance payerns (B-III) Health care informahon technology in the form of Electronic medical records (A-III) Computer physician order entry (B-II) Clinical decision support (B-II)

ENTEROBACTERII ȘI CARBAPENEMAZE q Prevalența bacteriilor gram negahve anhbiohc rezistente este în creștere în multe țări europene q MDR = mulhdrug resistance definește tulpini rezistente la 3 sau mai multe clase reprezentahve de agenți anhmicrobieni q XDR = extensive drug resistance rezistența la toate clasele, mai puțin una sau doua clase q PDR = pandrug resistance rezistența la toate clasele de anhbiohce disponibile M Souli et al, Eurosurveillance, 2008

Redefinirea ESKAPE ca ESCAPE E Enterococcus faecium S Staphylococcus aureus C Clostridium difficile Aceasta redefinire include noi patogeni Cresterea virulentei C. difficile A Acinetobacter baumannii P Pseudomonas aeruginosa E Enterobacteriaceae Enterobacteriaceae includ K. pneumoniae, Enterobacter spp., si alte specii rezistente ca Escherichia coli si Proteus spp. Peterson LR. Clin Infect Dis. 2009;49:992

Cal toriile au un rol major în r spândirea germenilor multirezisten!i 16

Scorul Carmeli Bacterii și Fungi

?,(2#\.(1&(%#)-&.`##,01% INFEC!II COMUNITARE INFEC!II NOSOCOMIALE INFEC!II COMUNITARE Germeni cu sensibilitate la AB posisbil p"strat" INFEC!II ASOCIATE ASISTEN!EI MEDICALE G-neg/poz posibil MDR ± ESBL INFEC!II NOSOCOMIALE MRSA G-neg MDR: + non-fermentativi: -!piocianic -!acinetobacter

Evaluarea riscului - Carmeli A. Contactul cu sectorul sanitar: 1) Fără contact 2) Contact fără proceduri invazive 3) Contacte repetate cu proceduri invazive 1 2 3 B. Tratament AB: 1) Fără AB 2) Cu AB în antecedente C. CaracterisNcile pacientului: 1) Tânăr fără comorbidităţi 2) Vârstnic cu comorbidităţi 3) Pacient imunodeprimat: Ø AIDS Ø BPOC Ø Cancer Ø BMT 1 2 1 2 3 Scor: 1,2 sau 3

:1#).#8(,##%*&1'&)#%#'8,#.(`#% S,I%)R""#)C.+,"-'(%# Infec ii asociate îngrijirilor de s n tate S,I%)R""#,C$C)C."'9%#!!##7,%+.C)C)+9#!!!"#$%&'(%)*(!!!!+,-*.(//*!0*12*-*/$3!!!##7,%+.C)C)+9#=#9'#7#!!!"#$%&#!Y#$%)(%-C(!!!!+#!4*12*-*/$3!=#9'#7#!!##<=T2#)C.+,"-'(#!!##Z%(.%,"#0%#$&"-'9#!!##<=T2#0%#$&"-'9#!!##5#!6%('7,%$*(!!!!2)",%-CQ')-%(#$&&B#!!##7"C)"',")#!!##Z%(.%,"#<4=## 7(CQ9%.%#&C-%,R"'9%# &%,-(+#2LM# 7(CQ9%.%#&C-%,R"'9%# &%,-(+#2LM# 7(CQ9%.%# &C-%,R"'9%# &%,-(+#2LM# VWX42# 42# 42#@#%,C(.%#

Carmeli 1 Carmeli 2 Sari direct aici! Carmeli 3 Infecţii comunitare Ampicilină Amoxi/clav FQ Levo/Moxi po CGII/III Macrolide Infecţii asociate îngrijirilor medicale Ertapenem Aminoglicozide ±FQ Levo/Moxi po/i.v. CGIII/IV C-antiPs. βlactami+i.β lactamaze (Amoxi/clav SR, ES) Linezolid/Vancomicină Macrolide Infecţii nosocomiale Imipenem/Meropenem Aminoglicozide FQ GIV Moxi iv CGIII antips CGIV: Cefepim, Cefpirom Linezolid / Vancomicină Macrolide

?8'9+'(%'#("$)+9+"#A'(.%9"@9"[%# 2B#AC,-',)-#)+#$%)-C(+9#$',"-'(D# EF! G*(*#)C,-')-# HF! AC,-')-#I*(*#&(C)%0+("#",8'J"8%# KF! AC,-')-%#I(%)8%,-%#)+#&(C)%0+("#",8'J"8%# LB#M%('&"%#)+#2L#\"#2GD# EF! G*(*#2L#\"X$'+#2G# HF! A+#2L#\"X$'+#2G#(%)%,-%#)+#'JC9"# AB#A'(')-%("$N)"9%#&')"%,-+9+"D# EF! MO,*(#P#I*(*##)C@.C(Q"0"-*R"# HF!!O($-,")#P#)+##)C@.C(Q"0"-*R"# KF! S.+,C)C.&(C."$D## "! 2S4T# "! L7UA# "! A',)%(# "! L<M# 1 2 3 1 2 1 2 3 Score : 1, 2 or 3

Terapia Infectiilor fungice invazive Carmeli-like 1 Carmeli-like 2 Carmeli-like 3 IFI comunitare IFI asociate îngrijirilor de s"n"tate IFI Nosocomiale Fluconazol Itraconazol Caspo (AI) Anidula (AI) Mica (AI) Voriconazol Posaconazol AMB Fluconazol Itraconazol Neutropenic: Caspofungin Voriconazol Posaconazol Non-neutropenic: Caspofungin Anidulafungin Micafungin Voriconazol Posaconazol

±Sepsis Pacientul TI Sepsis Sever Soc septic Non-neutropenic F 0 + factt de risc Neutropenic F 0 PMN<1000/mm 3 PCT <1 >1 AB + AF cu spectru ultralarg 72h Dezescaladare Completa * 1,3-!-D-glucans Neg 1,3-!-D-glucans Poz AB AB + AF

Sugestii în vederea ini#ierii TAF în TI de la practica curent" la ghiduri 2013 Suspected IFI - Carmeli-like Score G')]B#0%#("$)#&-B# 2$&B#T&&# G')-B#0%#("$)#&-B% A',0"0'#$&&B#!U=#^2SF#X#AT7#^ASSSF# A'(.%9"P9"[%#E#X#H# G*(*#'JC9"#',-%("C(# G*(*#0'-%#9C)'9%# %&"0%."C9C_")%#0%## AB#,C,@'9Q")',$# A'(.%9"#P9"[%#H#$'+#K#?e&+,%(%#9'#'JC9# 4'-%#9C)'9%#%&"0%."C9C_"%## 0%#=#9'#G9+)C,'JC9#'#AB#'9Q")',$X#,C,@'9Q")',$# A'(.%9"@9"[%#E# G*(*#)C,-')-#)+# $%)-C(+9#$',"-'(# GaW#bcc._XJ"# A'(.%9"@9"[%#H## S,I%)R""#'$C)"'-%# :,_("d"("9c(#0%# $*,*-'-%#!AT7##!2V4#!<SA2#!U=#!7UT`# b0)>b&7+108&)#.% AT7#X#2V4#X#<SA2#X#!U=``## Neutropenic AT7#^2SF#!U=#^LSF# 2GLaA#^LSF# <SA2^LSSF# a?()$#$0s(%010-(1#)*#()(%2&9&1(% ** Vezi criteriile de diferentiere

Criteriile de diferenhere Cancidas Micafungin Anidulafungin Singura cu indicahe in aspergiloza Singura cu indicahe in terapia de prima intenhe Spectrul cel mai larg in vitro Anomalii suplimentare hematologice (anemie, neutropenie, leucopenie) Avertizare FDA/EMEA cu privire la riscul de HCC Singura cu indicatie la copilul < 1 an Cele mai putine interactiuni medicamentoase Indicata in Insuficienta hepatica severa P-Ch >9

Scorul de agresivitate bacteriană şi corespondenţa cu scorul Carmeli

T)C(#0%#'_(%$"8"-'-%#'#$-'/9C)C)+9+"# 20%(%,R'# T)C(#0%#'_(%$"8"-'-%# K# H# E# c# c% icg# kcg# fk5ejg# <=T2# <=T2 <TT2 <=T2 <TT2 <TT2# hfg# bfg# ih5jhgg# L"C/9.#

AC(%9'R"%D#T)C(+9#0%#'_(%$"8"-'-%#'# $-'/9C)C)+9+"#@#T)C(+9#A'(.%9"# T)C(#0%#'_(%$"8"-'-%# K# H# E# c# <=T2# <=T2 <TT2 <=T2 <TT2 <TT2# MX!Xa# MX!Xa Ue' MX!Xa Ue' Ue'# K# H# E# T)C(+9#A'(.%9"# dj%d&#.08,()#)b%vjv().0'#.#)5b%eje#)&s0,#$b%t_(j%t_(.#,#)5%

<','_%.%,-+9#)'-%-%(+9+"#8%,C$# )%,-('9# T)C(#0%#'_(%$"8"-'-%# K# H# E# c# <=T2# <=T2 <TT2 <=T2 <TT2 <TT2# l,9c)+"(%'#a!a# l,9c)+"(%'#a!a# <%,R",%(%'#A!A## :,#I+,)R"%#0%# (%J+9-'-+9#79%eS4# <%,R",%(%'#A!A## :,#I+,)R"%#0%# (%J+9-'-+9#79%eS4# <','_%.%,-+9#A!A#

Cam așa ceva...